| Year |
Citation |
Score |
| 2023 |
Chen Y, Zhang S, Li Z, Yin B, Liu Y, Zhang L. Discovery of a dual-target inhibitor of CDK7 and HDAC1 that induces apoptosis and inhibits migration in colorectal cancer. Chemmedchem. e202300281. PMID 37821774 DOI: 10.1002/cmdc.202300281 |
0.316 |
|
| 2022 |
Sun G, Zhang Q, Liu Y, Xie P. Role of Phosphatidylinositol 3-Kinase and Its Catalytic Unit PIK3CA in Cervical Cancer: A Mini-Review. Applied Bionics and Biomechanics. 2022: 6904769. PMID 36046780 DOI: 10.1155/2022/6904769 |
0.3 |
|
| 2022 |
Peng Y, Zuo W, Zhou H, Miao F, Zhang Y, Qin Y, Liu Y, Long Y, Ma S. EXPLICIT-Kinase: a gene expression predictor for dissecting the functions of the Arabidopsis kinome. Journal of Integrative Plant Biology. PMID 35446465 DOI: 10.1111/jipb.13267 |
0.358 |
|
| 2021 |
Wen J, Hu H, Chen M, Yang H, Zhao Y, Liu Y. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review. Journal of Immunology Research. 2021: 2324400. PMID 34966823 DOI: 10.1155/2021/2324400 |
0.304 |
|
| 2021 |
Liu Y, Fu L, Wu J, Liu M, Wang G, Liu B, Zhang L. Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy. European Journal of Medicinal Chemistry. 229: 114056. PMID 34942431 DOI: 10.1016/j.ejmech.2021.114056 |
0.304 |
|
| 2021 |
Kenchappa RS, Liu Y, Argenziano MG, Banu MA, Mladek AC, West R, Luu A, Quiñones-Hinojosa A, Hambardzumyan D, Justilien V, Leitges M, Sarkaria JN, Sims PA, Canoll P, Murray NR, et al. Protein kinase C and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. Cell Reports. 37: 110054. PMID 34818553 DOI: 10.1016/j.celrep.2021.110054 |
0.384 |
|
| 2021 |
Finlay MRV, Barton P, Bickerton S, Bista M, Colclough N, Cross DAE, Evans L, Floc'h N, Gregson C, Guérot CM, Hargreaves D, Kang X, Lenz EM, Li X, Liu Y, et al. Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance. Journal of Medicinal Chemistry. PMID 34491761 DOI: 10.1021/acs.jmedchem.1c01055 |
0.31 |
|
| 2020 |
Liu J, Ma J, Liu Y, Xia J, Li Y, Wang ZP, Wei W. PROTACs: a novel strategy for cancer therapy. Seminars in Cancer Biology. PMID 32058059 DOI: 10.1016/J.Semcancer.2020.02.006 |
0.32 |
|
| 2020 |
Fang E, Wang X, Wang J, Hu A, Song H, Yang F, Li D, Xiao W, Chen Y, Guo Y, Liu Y, Li H, Huang K, Zheng L, Tong Q. Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression. Theranostics. 10: 1555-1571. PMID 32042322 DOI: 10.7150/thno.37383 |
0.322 |
|
| 2019 |
Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen D, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, ... ... Liu Y, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. The Journal of Clinical Investigation. PMID 31855575 DOI: 10.1172/JCI129126 |
0.353 |
|
| 2019 |
Li H, Yang F, Hu A, Wang X, Fang E, Chen Y, Li D, Song H, Wang J, Guo Y, Liu Y, Li H, Huang K, Zheng L, Tong Q. Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression. Embo Molecular Medicine. e10835. PMID 31709724 DOI: 10.15252/emmm.201910835 |
0.355 |
|
| 2019 |
Kenchappa R, Luu A, West R, Mladek A, Sarkaria J, Liu Y, Murray N, Fields A, Rosenfeld S. CSIG-13. PROTEIN KINASE CI DRIVES BOTH TUMOR INVASION AND PROLIFERATION AND IS A COMPELLING TARGET FOR THE TREATMENT OF GLIOBLASTOMA Neuro-Oncology. 21: vi46-vi46. DOI: 10.1093/Neuonc/Noz175.1189 |
0.31 |
|
| 2018 |
Du J, Li Y, Sun X, Yu L, Jiang H, Cao Q, Shang J, Sun M, Liu Y, Shu K, Liu J, Yong T, Liu W, Yang F, Wang X, et al. Characterization of a splice variant of soybean ERECTA devoid of an intracellular kinase domain in response to shade stress. Journal of Genetics. 97: 1353-1361. PMID 30555083 |
0.336 |
|
| 2018 |
Misale S, Fatherree JP, Cortez E, Li C, Bilton SJ, Timonina D, Lee D, Gomez-Caraballo M, Greenberg M, Nangia V, Greninger P, Egan RK, McClanaghan JD, Stein GT, Murchie E, ... ... Liu Y, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30327306 DOI: 10.1158/1078-0432.Ccr-18-0368 |
0.39 |
|
| 2018 |
Hansen R, Firdaus SJ, Li S, Janes MR, Zhang J, Liu Y, Zarrinkar PP. An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors. Scientific Reports. 8: 14312. PMID 30254226 DOI: 10.1038/S41598-018-32683-W |
0.384 |
|
| 2018 |
Wang JR, Shen GN, Luo YH, Piao XJ, Shen M, Liu C, Wang Y, Meng LQ, Zhang Y, Wang H, Li JQ, Xu WT, Liu Y, Sun HN, Han YH, et al. The compound 2-(naphthalene-2-thio)-5,8-dimethoxy-1,4-naphthoquinone induces apoptosis via reactive oxygen species-regulated mitogen-activated protein kinase, protein kinase B, and signal transducer and activator of transcription 3 signaling in human gastric cancer cells. Drug Development Research. PMID 30222185 DOI: 10.1002/Ddr.21442 |
0.344 |
|
| 2018 |
Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li LS, Ren P, Liu Y, Zarrinkar PP. The reactivity-driven biochemical mechanism of covalent KRAS inhibitors. Nature Structural & Molecular Biology. PMID 29760531 DOI: 10.1038/S41594-018-0061-5 |
0.766 |
|
| 2018 |
Du J, Jiang H, Sun X, Li Y, Liu Y, Sun M, Fan Z, Cao Q, Feng L, Shang J, Shu K, Liu J, Yang F, Liu W, Yong T, et al. Auxin and Gibberellins Are Required for the Receptor-Like Kinase ERECTA Regulated Hypocotyl Elongation in Shade Avoidance in Arabidopsis. Frontiers in Plant Science. 9: 124. PMID 29467786 DOI: 10.3389/fpls.2018.00124 |
0.349 |
|
| 2018 |
Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, ... ... Liu Y, ... ... Liu Y, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 172: 578-589.e17. PMID 29373830 DOI: 10.1016/J.Cell.2018.01.006 |
0.76 |
|
| 2018 |
Li L, Janes MR, Zhang J, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Feng J, Chen JH, Li S, Li S, Thach C, Liu Y, ... ... Liu Y, et al. Abstract 929: Discovery of novel covalent KRASG12C inhibitors that display high potency and selectivity in vitro and in vivo Cancer Research. 78: 929-929. DOI: 10.1158/1538-7445.Am2018-929 |
0.756 |
|
| 2018 |
Hansen R, Peters U, Babbar A, Chen Y, Feng J, Janes MR, Li L, Ren P, Liu Y, Zarrinkar PP. Abstract 686: Drugging an undruggable pocket: The biochemical mechanism of covalent KRASG12C inhibitors Cancer Research. 78: 686-686. DOI: 10.1158/1538-7445.Am2018-686 |
0.766 |
|
| 2018 |
Kessler L, Scholz C, Gualberto A, Liu Y, Burrows F. Abstract 4917: Tipifarnib is highly active in HRAS mutant lung squamous carcinoma tumor models Cancer Research. 78: 4917-4917. DOI: 10.1158/1538-7445.Am2018-4917 |
0.309 |
|
| 2018 |
Burrows FJ, Kessler L, Wu T, Gao X, Chen J, Hansen R, Li S, Thach C, Li S, Yu K, Kucharski J, Peters U, Feng J, Wang Y, Yao Y, ... ... Liu Y, et al. Abstract 3885: 11q13 amplification selects for sensitivity to the ERK inhibitor KO-947 in squamous cell carcinomas Cancer Research. 78: 3885-3885. DOI: 10.1158/1538-7445.Am2018-3885 |
0.731 |
|
| 2018 |
Burrows F, Wu T, Kessler L, Li S, Zhang J, Zarrinkar P, Li L, Cierpicki T, Grembecka J, Ren P, Liu Y. Abstract LB-A27: A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-A27 |
0.368 |
|
| 2017 |
He H, Xu J, Xie W, Guo QL, Jiang FL, Liu Y. Reduced state transition barrier of CDK6 from open to closed state induced by Thr177 phosphorylation and its implication in binding modes of inhibitors. Biochimica Et Biophysica Acta. PMID 29108955 DOI: 10.1016/j.bbagen.2017.11.001 |
0.3 |
|
| 2017 |
Gao B, Zhang L, Zheng Q, Zhou F, Klivansky LM, Lu J, Liu Y, Dong J, Wu P, Sharpless KB. Bifluoride-catalysed sulfur(VI) fluoride exchange reaction for the synthesis of polysulfates and polysulfonates. Nature Chemistry. 9: 1083-1088. PMID 29064495 DOI: 10.1038/Nchem.2796 |
0.393 |
|
| 2017 |
Wang H, Zhou F, Ren G, Zheng Q, Chen H, Gao B, Klivansky L, Liu Y, Wu B, Xu Q, Lu J, Sharpless KB, Wu P. SuFEx-Based Polysulfonate Formation from Ethenesulfonyl Fluoride-Amine Adducts. Angewandte Chemie (International Ed. in English). PMID 28792119 DOI: 10.1002/Anie.201701160 |
0.388 |
|
| 2017 |
Burrows F, Kessler L, Chen J, Gao X, Hansen R, Li S, Thach C, Darjania L, Yao Y, Wang Y, Zarieh A, Yu K, Wu T, Zhang J, Hu-Lowe D, ... ... Liu Y, et al. Abstract 5168: KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors Cancer Research. 77: 5168-5168. DOI: 10.1158/1538-7445.Am2017-5168 |
0.467 |
|
| 2017 |
Wu T, Kessler L, Li S, Purohit T, Li S, Miao H, Linhares B, Hansen R, Kucharski J, Wang Y, Yu K, Kempinska K, Ely T, Klossowski S, Zarieh A, ... ... Liu Y, ... ... Liu Y, et al. Abstract 5077: A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias Cancer Research. 77: 5077-5077. DOI: 10.1158/1538-7445.Am2017-5077 |
0.753 |
|
| 2016 |
Zeng Z, Wang RY, Qiu YH, Mak DH, Coombes K, Yoo SY, Zhang Q, Jessen K, Liu Y, Rommel C, Fruman DA, Kantarjian HM, Kornblau SM, Andreeff M, Konopleva M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget. PMID 27391151 DOI: 10.18632/Oncotarget.10397 |
0.413 |
|
| 2016 |
Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen JH, Firdaus SJ, Babbar A, Ren P, Liu Y. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discovery. PMID 26739882 DOI: 10.1158/2159-8290.Cd-15-1105 |
0.745 |
|
| 2015 |
Liu Y, Wang Y, Sun SF. [The relationship between phosphatidylinositol-3-kinases/protein-serine-threonine kinase signaling pathway and orthodontic tooth movement]. Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West China Journal of Stomatology. 29: 246-8, 252. PMID 21776846 |
0.382 |
|
| 2014 |
Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Acs Chemical Biology. 9: 1230-41. PMID 24730530 DOI: 10.1021/Cb500129T |
0.334 |
|
| 2014 |
Wachsberger PR, Lawrence YR, Liu Y, Rice B, Feo N, Leiby B, Dicker AP. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. Journal of Cancer Research and Clinical Oncology. 140: 573-82. PMID 24500492 DOI: 10.1007/S00432-014-1594-6 |
0.326 |
|
| 2014 |
Hu H, Yu Z, Liu Y, Wang T, Wei Y, Li Z. The Aurora B kinase in Trypanosoma brucei undergoes post-translational modifications and is targeted to various subcellular locations through binding to TbCPC1. Molecular Microbiology. 91: 256-74. PMID 24224936 DOI: 10.1111/mmi.12458 |
0.346 |
|
| 2014 |
Ruiz-Heiland G, Zhao Y, Derer A, Braun T, Engelke K, Neumann E, Mueller-Ladner U, Liu Y, Zwerina J, Schett G. Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. Annals of the Rheumatic Diseases. 73: 771-9. PMID 23632195 DOI: 10.1136/annrheumdis-2012-202907 |
0.346 |
|
| 2014 |
Zeng Z, Wang R, Shi Y, Qiu Y, Mak DH, Coombes K, Yoo SY, Jessen K, Liu Y, Rommel C, Kantarjian HM, Kornblau SM, Fruman D, Andreeff M, Konopleva M. MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML Blood. 124: 3613-3613. DOI: 10.1182/Blood.V124.21.3613.3613 |
0.445 |
|
| 2013 |
Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, ... ... Liu Y, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chemistry & Biology. 20: 1364-74. PMID 24211136 DOI: 10.1016/J.Chembiol.2013.09.017 |
0.376 |
|
| 2013 |
Ziv C, Feldman D, Aharoni-Kats L, Chen S, Liu Y, Yarden O. The N-terminal region of the Neurospora NDR kinase COT1 regulates morphology via its interactions with MOB2A/B. Molecular Microbiology. 90: 383-99. PMID 23962317 DOI: 10.1111/mmi.12371 |
0.353 |
|
| 2013 |
Xu N, Yuan H, Liu W, Li S, Liu Y, Wan J, Li X, Zhang R, Chang Y. Activation of RAW264.7 mouse macrophage cells in vitro through treatment with recombinant ricin toxin-binding subunit B: involvement of protein tyrosine, NF-κB and JAK-STAT kinase signaling pathways. International Journal of Molecular Medicine. 32: 729-35. PMID 23820591 DOI: 10.3892/ijmm.2013.1426 |
0.392 |
|
| 2013 |
Zheng Y, Zheng M, Ling X, Liu Y, Xue Y, An L, Gu N, Ji M, Jin M. Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 3523-30. PMID 23664099 DOI: 10.1016/j.bmcl.2013.04.039 |
0.301 |
|
| 2013 |
Zheng M, Zheng Y, Xue Y, Liu Y, An L, Zhang L, Ji M, Xue B, Wu X, Gong X, Gu N, Zhan X. Synthesis and quantum chemical studies of new 4-aminoquinazoline derivatives as Aurora A/B kinase inhibitors. Chemical Biology & Drug Design. 81: 399-407. PMID 23279802 DOI: 10.1111/cbdd.12089 |
0.325 |
|
| 2013 |
So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, et al. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. The Journal of Biological Chemistry. 288: 5718-31. PMID 23275335 DOI: 10.1074/Jbc.M112.379446 |
0.403 |
|
| 2013 |
Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 27: 586-94. PMID 23090679 DOI: 10.1038/Leu.2012.276 |
0.409 |
|
| 2013 |
Ostrem JM, Peters U, Ren P, Liu Y, Wells JA, Shokat KM. Abstract LB-311: Development of mutant-specific small molecule inhibitors of K-Ras. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-311 |
0.766 |
|
| 2012 |
Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Research and Treatment. 136: 673-82. PMID 23085766 DOI: 10.1007/S10549-012-2298-8 |
0.355 |
|
| 2012 |
Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 120: 2679-89. PMID 22826565 DOI: 10.1182/Blood-2011-11-393934 |
0.488 |
|
| 2012 |
Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, Rommel C, Firestein GS. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. The American Journal of Pathology. 180: 1906-16. PMID 22433439 DOI: 10.1016/J.Ajpath.2012.01.030 |
0.384 |
|
| 2012 |
GarcÃa-GarcÃa C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2603-12. PMID 22407832 DOI: 10.1158/1078-0432.Ccr-11-2750 |
0.375 |
|
| 2012 |
Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 485: 55-61. PMID 22367541 DOI: 10.1038/Nature10912 |
0.7 |
|
| 2012 |
Yu Z, Liu Y, Li Z. Structure-function relationship of the Polo-like kinase in Trypanosoma brucei. Journal of Cell Science. 125: 1519-30. PMID 22275435 DOI: 10.1242/jcs.094243 |
0.36 |
|
| 2012 |
De P, Sun Y, Wu H, Rommel C, Liu Y, Dey N, Leyland-Jones B. Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway. Journal of Clinical Oncology. 30: 626-626. DOI: 10.1200/Jco.2012.30.15_Suppl.626 |
0.405 |
|
| 2012 |
Tabernero J, Cervantes A, Gordon MS, Chiorean EG, Burris HA, Macarulla T, Perez-Fidalgo A, Martin M, Jessen K, Liu Y, Le T, Rommel C, Berk GI, Bui LA, Infante JR. Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Ct-02 |
0.325 |
|
| 2012 |
Infante JR, Tabernero J, Burris HA, Macarulla T, Martin M, Liu Y, Jessen K, Koczon E, Rommel C, Klein PM, Berk GI, Bui LA, Gordon MS. Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies Cancer Research. 72: 5588-5588. DOI: 10.1158/1538-7445.Am2012-5588 |
0.338 |
|
| 2012 |
Wang S, Lan L, Janes M, Jessen K, Kessler L, Kucharski J, Guo XX, Staunton J, Elia M, Banerjee U, Stewart J, Darjania L, li L, Chan K, Martin M, ... ... Liu Y, et al. Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer Cancer Research. 72: 3753-3753. DOI: 10.1158/1538-7445.Am2012-3753 |
0.409 |
|
| 2012 |
Janes MR, Guo X, Elia M, Staunton J, Jessen K, Rommel C, Liu Y. Abstract 2812: mTOR kinase mediates dissemination and colonization of breast cancer metastasis Cancer Research. 72: 2812-2812. DOI: 10.1158/1538-7445.Am2012-2812 |
0.346 |
|
| 2012 |
Kessler L, Jessen K, Janes M, Staunton J, Kucharski J, Guo X, Elia M, Banerjee U, Lan L, Wang S, Stewart J, Luzader A, Darjania L, Li L, Chan K, ... ... Liu Y, et al. Abstract 2745: INK128, a TORC1/2 kinase inhibitor, enhances the efficacy of cytotoxic therapies in endometrial tumor models Cancer Research. 72: 2745-2745. DOI: 10.1158/1538-7445.Am2012-2745 |
0.399 |
|
| 2012 |
Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzman M, Grueso J, Aura C, Perez J, Jesen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M. Abstract 1811: Antitumor activity of lapatinib in combination with the dual mTORC1/2 inhibitor INK-128 in breast tumors resistant to anti-HER2 therapy Cancer Research. 72: 1811-1811. DOI: 10.1158/1538-7445.Am2012-1811 |
0.383 |
|
| 2011 |
Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, et al. Defining the role of TORC1/2 in multiple myeloma. Blood. 118: 6860-70. PMID 22045983 DOI: 10.1182/Blood-2011-03-342394 |
0.425 |
|
| 2011 |
Mao T, Shao M, Qiu Y, Huang J, Zhang Y, Song B, Wang Q, Jiang L, Liu Y, Han JD, Cao P, Li J, Gao X, Rui L, Qi L, ... ... Liu Y, et al. PKA phosphorylation couples hepatic inositol-requiring enzyme 1alpha to glucagon signaling in glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America. 108: 15852-7. PMID 21911379 DOI: 10.1073/Pnas.1107394108 |
0.307 |
|
| 2011 |
Liu Y, Lv L, Xiao W, Gong C, Yin J, Wang D, Sheng H. Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation. Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban. 31: 365. PMID 21671179 DOI: 10.1007/s11596-011-0382-7 |
0.301 |
|
| 2011 |
Fruman DA, Janes MR, Mallya S, Vu CC, Shieh MP, Lilly MB, Sender LS, Martin MB, Ren P, Liu Y, Rommel C. The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models Blood. 118: 2585-2585. DOI: 10.1182/Blood.V118.21.2585.2585 |
0.372 |
|
| 2011 |
Maiso P, Liu Y, Azab AK, Morgan B, Azab F, Sacco A, Reagan M, Ngo HT, Liu Y, Zhang Y, Lin C, Roccaro AM, Rommel C, Ghobrial IM. Role of TORC1 and TORC2 in Multiple Myeloma Blood. 118: 1815-1815. DOI: 10.1182/Blood.V118.21.1815.1815 |
0.424 |
|
| 2011 |
Garcia-Garcia C, Serra V, Scaltriti M, Ibrahim Y, Guzman M, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J. Abstract 653: Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models Cancer Research. 71: 653-653. DOI: 10.1158/1538-7445.Am2011-653 |
0.459 |
|
| 2011 |
Jessen KA, Kessler L, Kucharski J, Guo X, Staunton J, Elia M, Janes M, Lan L, Wang S, Stewart J, Darjania L, Li L, Chan K, Martin M, Ren P, ... ... Liu Y, et al. Abstract 4501: INK1117: A potent and orally efficacious PI3Kα-selective inhibitor for the treatment of cancer Cancer Research. 71: 4501-4501. DOI: 10.1158/1538-7445.Am2011-4501 |
0.514 |
|
| 2011 |
Wang S, Jessen K, Kessler L, Kucharski J, Lan L, Guo X, Staunton J, Elia M, Stewart J, Darjania L, Li L, Chan K, Martin M, Ren P, Rommel C, ... Liu Y, et al. Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer Cancer Research. 71: 4486-4486. DOI: 10.1158/1538-7445.Am2011-4486 |
0.432 |
|
| 2011 |
Kessler L, Jessen K, Janes M, Staunton J, Kucharski J, Guo X, Elia M, Banerjee U, Lan L, Wang S, Stewart J, Luzader A, Darjania L, Li L, Chan K, ... ... Liu Y, et al. Abstract A172: INK128, an orally active TORC1/2 kinase inhibitor, displays enhanced efficacy when combined with cytotoxic agents. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A172 |
0.41 |
|
| 2011 |
Jessen K, Kessler L, Kucharski J, Guo X, Staunton J, Janes M, Elia M, Banerjee U, Lan L, Wang S, Stewart J, Luzader A, Darjania L, Li L, Chan K, ... ... Liu Y, et al. Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A171 |
0.512 |
|
| 2010 |
Wei L, Gao X, Warne R, Hao X, Bussiere D, Gu XJ, Uno T, Liu Y. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1. Bioorganic & Medicinal Chemistry Letters. 20: 3897-902. PMID 20627557 DOI: 10.1016/j.bmcl.2010.05.019 |
0.356 |
|
| 2010 |
Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, et al. A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. Journal of Medicinal Chemistry. 53: 5439-48. PMID 20604564 DOI: 10.1021/Jm901808W |
0.333 |
|
| 2010 |
Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, et al. The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nature Chemical Biology. 6: 244. PMID 20154668 DOI: 10.1038/Nchembio0310-244B |
0.783 |
|
| 2010 |
Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, et al. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nature Chemical Biology. 6: 117-24. PMID 20081827 DOI: 10.1038/Nchembio.293 |
0.801 |
|
| 2010 |
Liu Y, László C, Liu Y, Liu W, Chen X, Evans SC, Wu S. Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation. Neoplasia (New York, N.Y.). 12: 61-8. PMID 20072654 DOI: 10.1593/Neo.91354 |
0.305 |
|
| 2010 |
Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 16: 205-13. PMID 20072130 DOI: 10.1038/Nm.2091 |
0.496 |
|
| 2010 |
Cano OD, Polar Y, Liu Y, Ivan M, Fearn K, Ding J, Badve SS, Sledge GW, Loehrer PJ, Cardoso AA. Chemobiological screening for identification of molecular targets for thymic epithelial cancers. Journal of Clinical Oncology. 28: 10527-10527. DOI: 10.1200/Jco.2010.28.15_Suppl.10527 |
0.346 |
|
| 2010 |
Maiso P, Azab A, Liu Y, Zhang Y, Azab F, Sacco A, Ngo HT, Liu Y, Morgan B, Rommel C, Anderson KC, Roccaro AM, Ghobrial IM. Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma Blood. 116: 133-133. DOI: 10.1182/Blood.V116.21.133.133 |
0.46 |
|
| 2010 |
Kessler L, Wang S, Guo X, Kucharski J, Staunton J, Lan L, Elia M, Stewart J, Brown J, Li L, Chan K, Martin M, Ren P, Jessen K, Rommel C, ... Liu Y, et al. Abstract 4496: INK128, an orally active TORC1/2 kinase inhibitor, shows broad antitumor activity and enhances efficacy of cytotoxic as well as targeted agents Cancer Research. 70: 4496-4496. DOI: 10.1158/1538-7445.Am10-4496 |
0.448 |
|
| 2010 |
Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Zaheer NA, Mehta R, Badve S, Rommel C, Sledge GW. Abstract 4490: INK128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in a VEGF-reinforced murine model of breast cancer and enhances efficacy of bevacizumab Cancer Research. 70: 4490-4490. DOI: 10.1158/1538-7445.Am10-4490 |
0.375 |
|
| 2010 |
Wang S, Kessler L, Kucharski J, Lan L, Guo X, Staunton J, Elia M, Stewart J, Brown J, Li L, Chan K, Martin M, Ren P, Jessen K, Rommel C, ... Liu Y, et al. Abstract 4488: INK128: An orally active TORC1/2 kinase inhibitor demonstrates potent antitumor activity in preclinical models of renal cell carcinoma Cancer Research. 70: 4488-4488. DOI: 10.1158/1538-7445.Am10-4488 |
0.466 |
|
| 2010 |
Fruman DA, Janes MR, Limon JJ, So L, Chen J, Martin MB, Ren P, Liu Y, Rommel C. Abstract 1798: TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than rapamycin Cancer Research. 70: 1798-1798. DOI: 10.1158/1538-7445.Am10-1798 |
0.482 |
|
| 2010 |
Jessen K, Wang S, Guo X, Kessler L, Kucharski J, Staunton J, Lan L, Elia M, Stewart J, Brown J, Li L, Chan K, Martin M, Ren P, Rommel C, ... Liu Y, et al. Abstract 1668: Pharmacodynamic biomarker development for INK128, a potent and selective inhibitor of TORC1/2 for the treatment of cancer Cancer Research. 70: 1668-1668. DOI: 10.1158/1538-7445.Am10-1668 |
0.44 |
|
| 2009 |
Prudkin L, Aura CM, Jimenez J, Scaltriti M, Ellis C, Gagnon R, Arbushites M, Liu Y, Koehler M, Baselga J. Clinical benefit of lapatinib-based therapy in patients with HER2-positive breast tumors expressing p95HER2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1048. PMID 27961096 DOI: 10.1200/Jco.2009.27.15_Suppl.1048 |
0.326 |
|
| 2009 |
Zhang G, Ren P, Gray NS, Sim T, Wang X, Liu Y, Che J, Dong W, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Wang Z, Seidel HM, et al. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II. Bioorganic & Medicinal Chemistry Letters. 19: 6691-5. PMID 19854052 DOI: 10.1016/J.Bmcl.2009.09.123 |
0.393 |
|
| 2009 |
Maerz S, Dettmann A, Ziv C, Liu Y, Valerius O, Yarden O, Seiler S. Two NDR kinase-MOB complexes function as distinct modules during septum formation and tip extension in Neurospora crassa. Molecular Microbiology. 74: 707-23. PMID 19788544 DOI: 10.1111/j.1365-2958.2009.06896.x |
0.385 |
|
| 2009 |
Liu Y, Warfield L, Zhang C, Luo J, Allen J, Lang WH, Ranish J, Shokat KM, Hahn S. Phosphorylation of the transcription elongation factor Spt5 by yeast Bur1 kinase stimulates recruitment of the PAF complex. Molecular and Cellular Biology. 29: 4852-63. PMID 19581288 DOI: 10.1128/Mcb.00609-09 |
0.724 |
|
| 2009 |
Barouch-Bentov R, Che J, Lee CC, Yang Y, Herman A, Jia Y, Velentza A, Watson J, Sternberg L, Kim S, Ziaee N, Miller A, Jackson C, Fujimoto M, Young M, ... ... Liu Y, et al. A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Molecular Cell. 33: 43-52. PMID 19150426 DOI: 10.1016/J.Molcel.2008.12.024 |
0.355 |
|
| 2009 |
Jessen K, Wang S, Kessler L, Guo X, Kucharski J, Staunton J, Lan L, Elia M, Stewart J, Brown J, Li L, Chan K, Martin M, Ren P, Rommel C, ... Liu Y, et al. Abstract B148: INK128 is a potent and selective TORC1/2 inhibitor with broad oral antitumor activity Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B148 |
0.53 |
|
| 2009 |
Guix M, Aura C, Jimenez J, Scaltriti M, Gomez H, Doval D, Ellis C, Gagnon R, Liu Y, Koehler M, Baselga J. Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2. Cancer Research. 69: 708. DOI: 10.1158/0008-5472.Sabcs-708 |
0.3 |
|
| 2008 |
Zhang G, Ren P, Gray NS, Sim T, Liu Y, Wang X, Che J, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Chow D, Martin Seidel H, Karanewsky DS, et al. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I. Bioorganic & Medicinal Chemistry Letters. 18: 5618-21. PMID 18793846 DOI: 10.1016/J.Bmcl.2008.08.104 |
0.416 |
|
| 2008 |
Andersen CB, Wan Y, Chang JW, Riggs B, Lee C, Liu Y, Sessa F, Villa F, Kwiatkowski N, Suzuki M, Nallan L, Heald R, Musacchio A, Gray NS. Discovery of selective aminothiazole aurora kinase inhibitors. Acs Chemical Biology. 3: 180-92. PMID 18307303 DOI: 10.1021/Cb700200W |
0.426 |
|
| 2007 |
Huang G, Chen S, Li S, Cha J, Long C, Li L, He Q, Liu Y. Protein kinase A and casein kinases mediate sequential phosphorylation events in the circadian negative feedback loop. Genes & Development. 21: 3283-95. PMID 18079175 DOI: 10.1101/gad.1610207 |
0.355 |
|
| 2007 |
Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, Wan Y, Ding P, Liu Y, Sun F, Schultz PG, et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proceedings of the National Academy of Sciences of the United States of America. 104: 270-5. PMID 17185414 DOI: 10.1073/Pnas.0609412103 |
0.514 |
|
| 2006 |
Okram B, Nagle A, Adrián FJ, Lee C, Ren P, Wang X, Sim T, Xie Y, Wang X, Xia G, Spraggon G, Warmuth M, Liu Y, Gray NS. A general strategy for creating "inactive-conformation" abl inhibitors. Chemistry & Biology. 13: 779-86. PMID 16873026 DOI: 10.1016/J.Chembiol.2006.05.015 |
0.323 |
|
| 2006 |
Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology. 2: 358-64. PMID 16783341 DOI: 10.1038/nchembio799 |
0.397 |
|
| 2006 |
Choi HS, Wang Z, Richmond W, He X, Yang K, Jiang T, Karanewsky D, Gu XJ, Zhou V, Liu Y, Che J, Lee CC, Caldwell J, Kanazawa T, Umemura I, et al. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorganic & Medicinal Chemistry Letters. 16: 2689-92. PMID 16524731 DOI: 10.1016/j.bmcl.2006.02.032 |
0.337 |
|
| 2006 |
Zhang Q, Liu Y, Gao F, Ding Q, Cho C, Hur W, Jin Y, Uno T, Joazeiro CA, Gray N. Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. Journal of the American Chemical Society. 128: 2182-3. PMID 16478150 DOI: 10.1021/Ja0567485 |
0.399 |
|
| 2006 |
Choi HS, Wang Z, Richmond W, He X, Yang K, Jiang T, Sim T, Karanewsky D, Gu XJ, Zhou V, Liu Y, Ohmori O, Caldwell J, Gray N, He Y. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1. Bioorganic & Medicinal Chemistry Letters. 16: 2173-6. PMID 16458503 DOI: 10.1016/J.Bmcl.2006.01.053 |
0.344 |
|
| 2006 |
Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, Mestan J, Fabbro D, Gray NS. Allosteric inhibitors of Bcr-abl-dependent cell proliferation Nature Chemical Biology. 2: 95-102. PMID 16415863 DOI: 10.1038/Nchembio760 |
0.429 |
|
| 2005 |
Han S, Zhou V, Pan S, Liu Y, Hornsby M, McMullan D, Klock HE, Haugen J, Lesley SA, Gray N, Caldwell J, Gu XJ. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 15: 5467-73. PMID 16199156 DOI: 10.1016/J.Bmcl.2005.08.097 |
0.336 |
|
| 2004 |
Wan Y, Hur W, Cho CY, Liu Y, Adrian FJ, Lozach O, Bach S, Mayer T, Fabbro D, Meijer L, Gray NS. Synthesis and target identification of hymenialdisine analogs. Chemistry & Biology. 11: 247-59. PMID 15123286 DOI: 10.1016/j.chembiol.2004.01.015 |
0.403 |
|
| 2004 |
Liu Y, Kung C, Fishburn J, Ansari AZ, Shokat KM, Hahn S. Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Molecular and Cellular Biology. 24: 1721-35. PMID 14749387 DOI: 10.1128/Mcb.24.4.1721-1735.2004 |
0.75 |
|
| 2003 |
Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Current Pharmaceutical Design. 9: 2043-59. PMID 14529415 DOI: 10.2174/1381612033454126 |
0.398 |
|
| 2003 |
Yang Y, Cheng P, He Q, Wang L, Liu Y. Phosphorylation of FREQUENCY protein by casein kinase II is necessary for the function of the Neurospora circadian clock. Molecular and Cellular Biology. 23: 6221-8. PMID 12917343 DOI: 10.1128/MCB.23.17.6221-6228.2003 |
0.304 |
|
| 2002 |
Yang Y, Cheng P, Liu Y. Regulation of the Neurospora circadian clock by casein kinase II. Genes & Development. 16: 994-1006. PMID 11959847 DOI: 10.1101/gad.965102 |
0.34 |
|
| 2002 |
Witucki LA, Huang X, Shah K, Liu Y, Kyin S, Eck MJ, Shokat KM. Mutant tyrosine kinases with unnatural nucleotide specificity retain the structure and phospho-acceptor specificity of the wild-type enzyme. Chemistry & Biology. 9: 25-33. PMID 11841936 DOI: 10.1016/S1074-5521(02)00091-1 |
0.813 |
|
| 2000 |
Liu Y, Witucki LA, Shah K, Bishop AC, Shokat KM. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities. Biochemistry. 39: 14400-8. PMID 11087392 DOI: 10.1021/Bi000437J |
0.806 |
|
| 2000 |
Bishop A, Buzko O, Heyeck-Dumas S, Jung I, Kraybill B, Liu Y, Shah K, Ulrich S, Witucki L, Yang F, Zhang C, Shokat KM. Unnatural ligands for engineered proteins: new tools for chemical genetics. Annual Review of Biophysics and Biomolecular Structure. 29: 577-606. PMID 10940260 DOI: 10.1146/Annurev.Biophys.29.1.577 |
0.713 |
|
| 1999 |
Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, Ubersax J, Blethrow J, Morgan DO, Shokat KM. Structural basis for selective inhibition of Src family kinases by PP1. Chemistry & Biology. 6: 671-8. PMID 10467133 DOI: 10.1016/S1074-5521(99)80118-5 |
0.772 |
|
| 1999 |
Yang F, Liu Y, Bixby SD, Friedman JD, Shokat KM. Highly efficient green fluorescent protein-based kinase substrates. Analytical Biochemistry. 266: 167-73. PMID 9888972 DOI: 10.1006/Abio.1998.2885 |
0.649 |
|
| 1999 |
Bishop AC, Kung CY, Shah K, Witucki L, Shokat KM, Liu Y. Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach Journal of the American Chemical Society. 121: 627-631. DOI: 10.1021/Ja983267V |
0.825 |
|
| 1998 |
Liu Y, Shah K, Yang F, Witucki L, Shokat KM. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorganic & Medicinal Chemistry. 6: 1219-26. PMID 9784863 DOI: 10.1016/S0968-0896(98)00099-6 |
0.787 |
|
| 1998 |
Bishop AC, Shah K, Liu Y, Witucki L, Kung C, Shokat KM. Design of allele-specific inhibitors to probe protein kinase signaling. Current Biology : Cb. 8: 257-66. PMID 9501066 DOI: 10.1016/S0960-9822(98)70198-8 |
0.798 |
|
| 1998 |
Liu Y, Shah K, Yang F, Witucki L, Shokat KM. Engineering Src family protein kinases with unnatural nucleotide specificity. Chemistry & Biology. 5: 91-101. PMID 9495830 DOI: 10.1016/S1074-5521(98)90143-0 |
0.813 |
|
| 1997 |
Shah K, Liu Y, Deirmengian C, Shokat KM. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proceedings of the National Academy of Sciences of the United States of America. 94: 3565-70. PMID 9108016 DOI: 10.1073/Pnas.94.8.3565 |
0.728 |
|
| Show low-probability matches. |